We are excited to announce our Series C financing today, an oversubscribed $100 million raise that will help us advance our brain-targeting chemistry pipeline for underserved central nervous system conditions. With the backing of our investors and the resources from this financing, we plan to move quickly into Phase 2 development in depression and bipolar depression, and to also advance a broad disease-modifying neuroimmunology therapy into Phase 1 development. Thanks to Newpath Partners for leading this round, as well as our new and existing investors. To read more about our funding and CNS work, click here: https://lnkd.in/gnzrDDn2
Congratulations!!! Wishing you great success!!
Congratulations Kevin and team.
Well done! Kevin !! Congrats !!
Congratulations Kevin! This is great news! Best wishes!
Congratulations!
Congrats Kevin
Principal at Monograph Capital Partners
1moCongratulations!! Thrilled to partner with you on this important journey. Great to be working with such an excellent team as well as a great group of new and existing investors.